https://www.selleckchem.com/pr....oducts/gsk2879552-2h
ses, and as they were enriched in patients with arterial dissections, may act as disease modifiers. Molecular testing for COL5A1 should be considered in patients with a phenotype overlapping with vascular Ehlers-Danlos syndrome and mFMD.Aim To evaluate changes in health-related quality of life (HRQoL) in a Phase II trial (NCT02155647) of treatment-naive patients with metastatic Merkel cell carcinoma treated with avelumab (15-month follow-up). Materials methods Mixed-effect Models for Repeated Measures were applied to HRQoL
Like
Comment
Share
